Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, CI Medical Co's PEG is 1. CI Medical Co's 5-Year TTM EBITDA Growth Rate is 19.6.
CI Medical Co's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2025 was 円45.90. Therefore, the Peter Lynch Fair Value for today is 円899.58.
As of today (2026-08-04), CI Medical Co's share price is 円1492.00. CI Medical Co's Peter Lynch fair value is 円899.58. Therefore, CI Medical Co's Price to Peter Lynch Fair Value Ratio for today is 1.66.
The historical rank and industry rank for CI Medical Co's Peter Lynch Fair Value or its related term are showing as below:
TSE:3540'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.73 Med: 1.02 Max: 1.66
Current: 1.66
During the past 10 years, the highest Price to Peter Lynch Fair Value Ratio of CI Medical Co was 1.66. The lowest was 0.73. And the median was 1.02.
TSE:3540's Price-to-Peter-Lynch-Fair-Value is not ranked
in the Consumer Packaged Goods industry.
Industry Median: 0.99
vs TSE:3540: 1.66
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
CI Medical Co (TSE:3540) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 19.6 instead of 15 in this case.
CI Medical Co's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
1492.00
/
899.58
=
1.66
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CI Medical Co Peter Lynch Fair Value Related Terms
CI Medical Co Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for CI Medical Co's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3540 vs PG, CL, KMB: Peter Lynch Fair Value Comparison
For the Household & Personal Products subindustry, CI Medical Co's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CI Medical Co Price-to-Peter-Lynch-Fair-Value vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, CI Medical Co's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where CI Medical Co's Price-to-Peter-Lynch-Fair-Value falls into.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CI Medical Co's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2025 was 円45.90.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of 円899.58 mean?
CI Medical Co (TSE:3540) has a Peter Lynch Fair Value of 円899.58 as of Aug. 04, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on CI Medical Co and its competitors. This is 88094% above median its historical median of 1.02. Over the past decade, CI Medical Co's Peter Lynch Fair Value has ranged from 0.73 to 1.66.
Is CI Medical Co's Peter Lynch Fair Value too high?
CI Medical Co's current Peter Lynch Fair Value of 円899.58 is 88094% above median its 10-year median of 1.02. Over the past 10 years, this metric has ranged from a low of 0.73 to a high of 1.66. Overall, CI Medical Co has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does CI Medical Co's Peter Lynch Fair Value compare to PG and CL?
CI Medical Co's Peter Lynch Fair Value of 円899.58 can be compared against companies in the Consumer Packaged Goods industry. The industry median Peter Lynch Fair Value is 0.99. Historically, CI Medical Co's own Peter Lynch Fair Value has ranged from 0.73 to 1.66 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Consumer Packaged Goods company?
The median Peter Lynch Fair Value among Consumer Packaged Goods companies is 0.99, based on 582 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on CI Medical Co and its competitors. For the Consumer Packaged Goods industry, the median Peter Lynch Fair Value is 0.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CI Medical Co's current Peter Lynch Fair Value is 円899.58, which is 88094% above median its own 10-year median of 1.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CI Medical Co stock overvalued right now?
CI Medical Co (TSE:3540) has a current Peter Lynch Fair Value of 円899.58. The stock's GF Value™ is 円2,121.23, compared to a current price of 円1,492.00 — trading 29.7% below its estimated fair value. The current Peter Lynch Fair Value is 円899.58, which is 88094% above median its 10-year median of 1.02. CI Medical Co's overall GF Score™ is 70/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For CI Medical Co (TSE:3540), the current Peter Lynch Fair Value is 円899.58 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CI Medical Co (TSE:3540) Overvalued in 2026?
Based on GuruFocus' analysis, CI Medical Co stock appears to be undervalued.
The current stock price of 円1,492.00 is trading 29.7% below its estimated GF Value™ of 円2,121.23.
Key valuation signals for TSE:3540:
Peter Lynch Fair Value: 円899.58 (88094% above median its 10-year median of 1.02)
GF Value™: 円2,121.23 vs. price of 円1,492.00 (29.7% below fair value)
No single metric tells the full story. See the TSE:3540 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CI Medical Co Ltd engages in the development, manufacturing, and sales of dental care products. It operates 3D design labs; it offers advertising and marketing services through its website "Dental Mall" and also manages oral health care website "Ci Mall" and "Dental Fit" through which it sells oral health products and dentures. It serves medical cooperatives, dental clinics, dental associations, health centers, dental colleges, veterinary clinics, nursing home care facilities, and dental dealers.
70GF Score
Get the complete analysis for TSE:3540
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3540 has been successfully added to your 
